Health Technology Assessment

This paper examines the views of US and European payers on the rapidly evolving fields of comparative effectiveness and relative effectiveness research.

The blog provides links to slide sets and posters relating to the value footprint of oncology treatments, treating obstructive sleep apnoea and sources of motivation in health care organisations.

This post reports on an Issues Panel which was held at the Spanish Health Economics Association Annual Conference which took place in Granada, Spain 17-19 June 2015. The title of the panel was: Developing cost effectiveness for decision making: what can be learnt from “Value Based Pricing”?

Rachel Meacock reports on the economics of elevated hospital mortality at weekends.

In June 2015 OHE’s Nancy Devlin gave a seminar at the Royal Statistical Society on the topic of patient-reported outcomes measures (PROMs) in health economics – providing an overview and highlighting key developments in the field.

This post summarises OHE’s activities at this year HTAi meeting in Oslo, June 2015. Topics include the effect of NICE decisions abroad and a new drug development paradigm.

This post summarises OHE’s activities at the upcoming HTAi meeting in Oslo, June 2015. Topics include the effect of NICE decisions abroad, a framework for developing formularies in MICs, a new drug development paradigm, and a comparison of EQ-5D-5L and EQ-5D-3L.

This blog contains a selection of the posters and presentations given by OHE at ISPOR Philadelphia in May 2015.

This mapping of priority-setting considers factors such as existence of HTA institutions and commitment to UHC (Brazil, Chile, Colombia, Mexico, Uruguay, Ghana, Kenya, Malawi, South Africa, Uganda, China, India, Indonesia, Myanmar, Philippines, Thailand and Vietnam).

Articles co-authored by Adrian Towse, Martina Garau, Donna Messner, and Penny Mohr exploring future expectations of drug relative effectiveness in Europe and comparative effectiveness in the USA just published online.


Subscribe to RSS - Health Technology Assessment